“…15,16 There are variable clinical responses when intravitreal bevacizumab is used to treat radiation retinopathy with some studies reporting reduction in haemorrhage, retinal oedema and neovascularisation with either improvement or maintenance of vision. 11,17,18 Shah et al 19 have explored intravitreal bevacizumab as a means of preventing or reducing the incidence of radiation maculopathy, with a reduced incidence of macular oedema at 2 years. Poku et al's 20 systematic review of the safety of intravitreal bevacizumab showed low rates of adverse events following treatment, and even then, it is unclear if quality of PIB has a role in these reported incidents.…”